Energy Expenditure and Body Composition in Pseudohypoparathyroidism 1a
|ClinicalTrials.gov Identifier: NCT01398774|
Recruitment Status : Active, not recruiting
First Posted : July 21, 2011
Last Update Posted : May 3, 2017
|Condition or disease|
|Pseudohypoparathyroidism Type 1A Albright Hereditary Osteodystrophy|
Pseudohypoparathyroidism 1a (PHP1a) is a disorder that is associated with many endocrine problems. People with PHP1a are at risk for the development of obesity. The objective of the study will help determine if obesity is related to abnormalities energy expenditure, meaning that people with PHP1a may not burn as many calories while at rest as those without the disorder.
In order to further evaluate obesity in PHP1a, investigators are planning to measure resting energy expenditure (REE), which is the amount of calories burned while completely at rest. Investigators will also evaluate body composition by looking at measures of growth and development and determining the amount of body fat using dual energy x-ray absorptiometry (DXA) as well as blood and urine biologic markers of obesity. The investigators plan to evaluate people with PHP1a at all weights.
|Study Type :||Observational|
|Actual Enrollment :||519 participants|
|Official Title:||Altered Resting Energy Expenditure as a Cause of Obesity in Pseudohypoparathyroidism 1a: A Pilot Study|
|Study Start Date :||June 2011|
|Primary Completion Date :||September 2015|
|Estimated Study Completion Date :||April 2018|
- Resting Energy Expenditure [ Time Frame: 30 minutes ]The subject will rest for 30 minutes in the lab prior to the start of the test. A 60-minute resting energy expenditure (REE) test will be performed between 7:00 and 10:00 A.M. with the subject resting quietly under a clear, plastic hood watching a videotape.
- Characterize body composition in patients with PHP1a. [ Time Frame: 12 months ]Body composition outcomes will be characterized by whole body lean mass and fat mass sex- and race-specific z-scores relative to height.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01398774
|United States, Pennsylvania|
|Children's Hospital of Philadelphia|
|Philadelphia, Pennsylvania, United States, 19104|
|Principal Investigator:||Michael A Levine, M.D.||Children's Hospital of Philadelphia|